UroGen Pharma - About the company
UroGen Pharma is a public company based in Ra anana (Israel), founded in 2004. It operates as a Developer of therapeutics to treat urothelial and specialty cancers. UroGen Pharma has raised $7M in funding from Sonostar Ventures. The company has 7 active competitors, including 1 funded and 3 that have exited. Its top competitors include companies like Protara Therapeutics, Asieris Pharmaceuticals and Tollys.
Company Details
Developer of therapeutics to treat urothelial and specialty cancers. The company uses proprietary technology RTGel to deliver targeted therapies which include "Jelmyto" for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer.
- Website
- Social
- Email ID
- @urogen.com
Key Metrics
Founded Year
2004
Location
Ra anana, Israel
Stage
Public
Total Funding
in 4 rounds
Latest Funding Round
Investors
Ranked
1st among
Similar Companies
Exit Details
Public
Legal entities associated with UroGen Pharma
UroGen Pharma is associated with 1 legal entity given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
Apr 27, 2004 | - | 404 | 364 |
Get your free copy of UroGen Pharma's company profile
UroGen Pharma's funding and investors
UroGen Pharma has raised a total funding of $7M over 4 rounds. Its first funding round was on May 22, 2013. Its latest funding round was a Post IPO round on Jul 27, 2023 for $120M. 4 investors participated in its latest round, which includes Sonostar Ventures, Pontifax, Magna Capital Partners and Bellco Capital.
UroGen Pharma has 12 institutional investors including Sonostar Ventures, Pontifax and .
Here is the list of recent funding rounds of UroGen Pharma:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Jul 27, 2023 | $120M | Post IPO | 8572838 | 4176391 | |
Mar 18, 2021 | $75M | Post IPO | 1635420 | 6564972 | |
2016 | Undisclosed | Series B | 9369 | 3275 |
Access funding benchmarks and valuations. Sign up today!View details of UroGen Pharma's funding rounds and investors
UroGen Pharma's Competitors and alternates
Top competitors of UroGen Pharma include Protara Therapeutics, Asieris Pharmaceuticals and Tollys. Here is the list of Top 10 competitors of UroGen Pharma, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st | 2004, Ra anana (Israel), Public | Developer of therapeutics to treat urothelial and specialty cancers | $7M | Sonostar Ventures, PontifaxÌý&²¹³¾±è;Ìý | 57/100 |
2nd |  Protara Therapeutics 2017, New York City (United States), Public | Developer of cell therapies to treat lymphatic malfunctions | - | Abingworth, Velan CapitalÌý&²¹³¾±è;Ìý | 61/100 |
3rd |  Asieris Pharmaceuticals 2010, Radnor (United States), Unfunded | Developer of drugs for the treatment of genitourinary tumors and other major diseases | - | - | 48/100 |
4th | Developer of drugs for treating cancer | $6.97M | 46/100 | ||
5th | Tengion 2004, Audubon (United States), Deadpooled | Regenerative medicine company developing neo-organs & neo-tissues. | $143M | Perceptive Advisors, Oak Investment PartnersÌý&²¹³¾±è;Ìý | 41/100 |
6th |  Rainer Theraputics 2010, San Leandro (United States), Deadpooled | Developer of antibody based therapeutics for bladder cancer | $80M | Inkef Capital, Tekla Capital ManagementÌý&²¹³¾±è;Ìý | 41/100 |
7th |  Anchiano Therapeutics 2004, Cambridge (United States), Public | Developer of gene therapy for the treatment of bladder cancer | - | 35/100 | |
8th | Telesta Therapeutics 1979, Montreal (Canada), Acqui-Hired | Develops biologics for the treatment of non-muscle-invasive bladder cancer (NMIBC) in humans | - | CRG, Ìý&²¹³¾±è;Ìý | 33/100 |
9th |  OncoSTING 2018, Baltimore (United States), Funding Raised | Developer of immunotherapy for bladder cancer | - | - | 26/100 |
10th |  CicloMed 2015, Kansas City (United States), Funding Raised | Developer of drugs for treating bladder cancer | - | 24/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on UroGen Pharma's competitors? Click to see the top ones
UroGen Pharma's Investments and acquisitions
UroGen Pharma has made no investments or acquisitions yet.
Reports related to UroGen Pharma
Here is the latest report on UroGen Pharma's sector:
View
News related to UroGen Pharma
Media has covered UroGen Pharma for a total of 31 events in the last 1 year, 14 of them have been about company updates and 2 about people movement.
•
MarketBeat•Apr 24, 2025•UroGen Pharma,
•
•
•
•
Seeking Alpha•Mar 10, 2025•UroGen Pharma
•
Business Wire•Mar 10, 2025•UroGen Pharma
•
Seeking Alpha•Mar 10, 2025•UroGen Pharma
•
•
Business Wire•Feb 20, 2025•UroGen Pharma
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
FAQ's about UroGen Pharma
Explore our recently published companies
- Fiidotherm - 1989 founded, Unfunded company
- Apiway - Indonesia based, 2018 founded, Unfunded company
- Aureus Group - Dubai based, 2023 founded, Unfunded company
- Q&D Circuits - Shenzhen based, 2004 founded, Public company
- CDM - 1994 founded, Unfunded company
- Microbe Plus - Lublin based, 2020 founded, Unfunded company
